Hetrombopag Olamine

Phase 1UNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Purpura, Thrombocytopenic, Idiopathic

Conditions

Purpura, Thrombocytopenic, Idiopathic

Trial Timeline

Apr 1, 2014 → —

NCT ID

NCT02403440

About Hetrombopag Olamine

Hetrombopag Olamine is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Purpura, Thrombocytopenic, Idiopathic. The current trial status is unknown. This product is registered under clinical trial identifier NCT02403440. Target conditions include Purpura, Thrombocytopenic, Idiopathic.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05944211	Phase 2	Recruiting	Jul 1, 2023	Jan 1, 2027	Chemotherapy-Induced Thrombocytopenia
NCT03977805	Phase 1	Completed	May 25, 2019	Jun 13, 2019	Healthy
NCT03603132	Phase 1	Completed	Jul 14, 2018	Aug 17, 2018	Immune Thrombocytopenia
NCT03557099	Phase 1/2	Completed	Jun 20, 2018	Jul 23, 2020	Severe Aplastic Anemia
NCT02614846	Phase 1	UNKNOWN	Aug 1, 2015	—	Chronic Idiopathic Thrombocytopenic Purpura
NCT02403440	Phase 1	UNKNOWN	Apr 1, 2014	—	Purpura, Thrombocytopenic, Idiopathic
NCT02409394	Phase 1	Completed	Mar 1, 2014	Apr 1, 2014	Healthy

Competing Products

20 competing products in Purpura, Thrombocytopenic, Idiopathic

See all competitors

Product	Company	Stage	Hype Score
E5501	Eisai	Phase 1	33
E5501 + Drug: E5501	Eisai	Phase 1	33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food	Eisai	Phase 1	33
Eltrombopag + Avatrombopag + Standard of care	Eisai	Phase 3	77
Placebo + Avatrombopag tablets	Eisai	Phase 2	52
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)	Eisai	Phase 2	52
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral	Eisai	Phase 1	33
AMG 531	Kyowa Kirin	Phase 2/3	65
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	52
Hetrombopag Olamine + matching placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	33
MK-8723 + Matching Placebo	Merck	Phase 1	33
Eltrombopag	Novartis	Phase 2	52
eltrombopag	Novartis	Phase 2	52
Eltrombopag	Novartis	Pre-clinical	23
Eltrombopag	Novartis	Phase 3	77
eltrombopag + placebo	Novartis	Phase 3	77
Eltrombopag + IVIG infusion	Novartis	Phase 3	77
eltrombopag olamine (SB-497115-GR)	Novartis	Phase 3	77
Eltrombopag Tablets + Eltrombopag PfOS	Novartis	Phase 3	77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved